medicine (e.g., calcium with calcitriol, aspirin with a statin, etc.), the availability of such combinations also opens up the market for the costlier drugs. As Nietzsche once said, "When you look deep into the abyss, the abyss looks back into you." Paradoxically, the same mechanism that causes reduction in prices might end up costing the patient more. This is especially important as the Department of Pharmaceuticals (DoP) data show that the costly + cheap medicine combinations occupy less than 10% of the pharmaceutical market and even in those, the reduction in prices is to the tune of 20% or less. Calcium/calcitriol combination is an exception-46.5% of available preparations contain calcitriol. [10] For those with impaired activation of vitamin D, calcium-calcitriol FDC offers both a cost and convenience advantage. Thus, wherever there is a genuine need for calcitriol therapy, calcium-calcitriol FDCs can be considered.
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Owing to the nuances involved, doctors may be tempted to eschew the use of FDCs completely-however, that would be akin to throwing the baby with the bathwater. Thus, the onus of choosing the right FDC for the right patient falls on the clinician. So, loop back to the original question-is calcitriol-calcium FDC a match made in heaven or hell? It depends on the matchmaker-the prescribing clinician. inflammatory cytokines, and other surrogate measures of cardiovascular risk. [1] However, the treatment protocol used for correcting vitamin D deficiency in that study is not commonly used in clinical practice (as per recommendations by different international guidelines like that from the Indian Academy of Pediatrics), and is definitely not "high-dose". [2] This is because the authors have used cholecalciferol at dose of 60,000 IU fortnightly (120,000 IU/month) for treating severe vitamin D deficiency (8.36 ± 5.45 ng/mL) which is lower than the standard recommendations of 60,000 IU cholecalciferol weekly for at least 6 weeks, and thereafter a maintenance dose of 60,000 IU monthly for preventing recurrence of vitamin D deficiency. [2] Hence, it is not surprising that vitamin D sufficiency was not obtained in the treatment group at the end of the study (26.89 ± 12.23 ng/mL). [1] Only 41.2% of children in the intervention group had serum 25OHD >30 ng/mL at the end of the study. [1] Vitamin D is a fat-soluble vitamin, sequestrated in the adipose tissue, hence vitamin D deficiency is more common and more severe in obese individuals, who also require higher doses for optimal correction of vitamin D deficiency. [3] [4] [5] Studies have consistently demonstrated that the non-bone mineral effects of vitamin D (pleiotropic benefits on cardiovascular system, glucose metabolism, nervous system, immune system, and cancers) are apparent at higher serum 25-hydroxy-vitamin D (25OHD) levels >30 ng/mL in contrast to >20 ng/mL which is considered to be sufficient to prevent adverse bone mineral outcomes. [6] [7] [8] Hence, it is likely that the authors did not document any meaningful impact of vitamin D supplementation on insulin resistance and CV risk factors, cause the majority of the children in the treatment group never attained vitamin D sufficiency (25OHD > 30 ng/mL) at the end of the study.
The D2d study, the largest blinded RCT published till date on impact of vitamin D on insulin resistance and prevention of prediabetes to diabetes progression showed that although there were no overall benefits after 2.5 years of vitamin D supplementation in people living with prediabetes who had a mean serum levels of vitamin D of 27 ng/mL at the start of the study. [9] However, subgroup analysis revealed that in a small cohort of 103 prediabetes individuals who had the most severe vitamin D deficiency (25OHD <12 ng/mL), vitamin D supplementation, and ensuring vitamin D sufficiency (25OHD >30 ng/mL) significantly reduced the hazard ratios of prediabetes progression to diabetes to 0.32 (95% CI 0.81-0.80) which is much better than the overall study rates of 0.92 (95% CI 0.78-1.08). [9] Dutta et al. demonstrated that vitamin D supplementation resulting in correction of vitamin D deficiency (25OHD levels improved from 17.04 ± 7.66 ng/mL to 35.47 ± 10.1 ng/mL) resulted in decreased prediabetes progression to diabetes and its increased reversal to normoglycemia, along with beneficial impact on insulin resistance and inflammatory cytokines, in a cohort of individuals from eastern India. [10] Another study from Kashmir showed similar results of the beneficial impact of vitamin D supplementation on reducing progression of prediabetes to diabetes with a reduction in fasting glucose, 2-hour plasma glucose, and HbA1c over a period of 1-year follow-up. [11] The problem is that with rampant, unmonitored vitamin D supplementation (nutraceuticals; without medical supervision) both in India and the western world, which is, unfortunately, increasing the occurrence of vitamin D intoxication; the prevalence of severe vitamin D deficiency in the general population has gone down over the last few decades. [12] It is very likely that these people who are living with the most severe form of vitamin D deficiency, are expected to get the maximal bone mineral and pleiotropic benefits of vitamin D supplementation once we ensure vitamin D sufficiency (25OHD >30 ng/mL). Therefore, further RCTs evaluating the pleiotropic benefits of vitamin D should primarily focus on them. Vitamin D is definitely not a panacea, and unmonitored prolonged vitamin D supplementation using supraphysiologic doses, especially parental, should be strongly discouraged.
